The table below applies the framework of this report to the listed names. These ratings are the own reading of publicly available information by Dart Consultants, not a broker consensus — institutional coverage of this sub-sector is thin, and where third-party targets exist they are noted and dated. This is not investment advice; please read the disclaimer on the final page.
| Company | Rating | Reference price | Valuation | Balance sheet | Key justification |
|---|---|---|---|---|---|
| Accent Microcell NSE: ACCENTMIC | HOLD | Rs 697 9 Sep 2026 | ~37x FY26 EPS of Rs 18.65; market cap ~Rs 1,670 cr | Essentially debt-free; gearing 0.01x; interest cover >60x | Best-quality business in the group — focused, export-led, high return on equity, self-funded expansion. But the stock has roughly tripled from its 52-week low while the capacity that justifies the re-rating has slipped twice and is not yet producing. |
| Sigachi Industries NSE: SIGACHI | SELL | Rs 37.6 10 Sep 2026 | ~64x trailing earnings on a depressed base; market cap ~Rs 1,435 cr; ~2.8x book | Debt-to-equity ~0.27x; prior warrant commitments unmet | The operating recovery is real, but the price already pays for a full normalisation. A proposed 11 crore warrant issue at Rs 26.40 implies ~29% dilution at a ~30% discount, and the criminal file from the June 2025 incident is unresolved with the chief executive personally named. See the company report for the full governance assessment. |
| Chemfield Cellulose | NOT RATED | — | Unlisted; stake acquired by Oji Holdings (TSE: 3861) | Not disclosed | No direct Indian listed exposure. Relevant as a competitive and valuation data point: a strategic upstream buyer paid for an Indian MCC platform. |
| Global majors IFF, Asahi Kasei, BASF, Ashland, Roquette, JRS, DFE | NOT RATED | — | Excipients are a small line inside much larger groups | Varies | None offers meaningful pure-play exposure to this theme. Buying them for excipient exposure means buying a diversified chemicals or nutrition business instead. |
FY26 delivered Rs 349 crore of operating revenue and Rs 43.9 crore of profit. If Unit-III Phase 1 contributes partially in FY27 and the traded share falls, a reasonable range is Rs 420–460 crore of revenue and Rs 52–58 crore of profit — earnings per share of roughly Rs 21.5 to Rs 24. At a 28–34x multiple, which is where a debt-free mid-teens grower with a delayed project might reasonably trade, that is Rs 600–815 per share against a reference price of Rs 697.
In other words: the current price already sits inside the range that successful execution would justify. That is the entire basis for a Hold rather than a Buy. Every figure in this paragraph after FY26 is an illustration of method, not a forecast — the point is the shape of the arithmetic, which a reader should redo with their own assumptions.
Upgrade Accent on: Unit-III Phase 1 in commercial production with derivative revenue disclosed separately; traded volume share falling below roughly 20%; realisation per tonne rising; or a meaningful pullback in the share price.
Downgrade Accent on: further unexplained delay at Unit-III; margin compression as new industry capacity lands; loss of a top-ten customer; or evidence that new tonnage is being sold into standard grades.
Upgrade Sigachi on: the proposed warrant issue completing on materially better terms, being scaled back or lapsing; two consecutive quarters at guided margin with MCC revenue share recovering toward historic levels; and resolution of the legal file without material financial liability.
Downgrade Sigachi on: the warrant issue completing largely as proposed; guidance missed for a third consecutive quarter; an adverse finding or additional liability in the Pashamylaram matter; or MCC revenue share continuing to fall.
Figures compiled from company filings, exchange disclosures, credit-rating publications and public market aggregators as at 12 September 2026. Prices move; the ratings above are anchored to the reference prices stated and become stale quickly.
| Rating | Expected total return over 12 months |
|---|---|
| BUY | 15% and above |
| HOLD | −5% to 15% |
| SELL | −5% and below |
Accent is smaller, debt-free, growing, higher-return and more expensive on every multiple. Its risk is project execution.
Sigachi is larger, levered, cheaper on normalised earnings and dearer on current ones. Its risk is whether normalisation happens at all, and on what terms.
We rate Accent HOLD because a good business is fully priced, and Sigachi SELL because a recovering one is priced as though the recovery were complete — before a 29% dilution and with an unresolved legal file.
